When Does GLP-1 Weight Loss Start? The First Month

“When does Ozempic start working?” is one of the most common questions in the first weeks on any GLP-1, and it usually carries an anxious subtext: is this doing anything yet? The honest answer from the trial data is that these drugs begin to work early — but “working” in month one mostly means appetite changes, not a dramatic drop on the scale. Here is what the evidence actually shows about GLP-1 weight loss onset, and why the first month looks the way it does.

If you want to see roughly where your loss might land over the coming months rather than the coming weeks, our GLP-1 weight loss projector maps a realistic curve from your starting point.

What the trials show about early onset

The clearest primary evidence comes from STEP-1, the 68-week pivotal trial of semaglutide 2.4 mg (Wegovy) published in the New England Journal of Medicine in 2021. In that trial, weight loss in the semaglutide group was already measurable at the first post-randomization assessment at week 4, and it kept building, reaching its lowest point around week 60 before the trial ended at week 68. The final average loss was about 14.9% of body weight, versus 2.4% on placebo.

Two things follow from that curve. First, yes — the drug starts nudging weight down within the first month for most people. Second, and more importantly, the bulk of the loss comes over the following year, not the first few weeks. The trajectory is a long, gradual slope, not a cliff.

In the STEP-1 semaglutide trial, measurable weight loss appeared by the first check-in at week 4 and kept building for over a year.

Why the first dose is deliberately slow

The reason month one is modest is baked into how these drugs are dosed. Both semaglutide and tirzepatide start at a sub-therapeutic dose on purpose:

Drug	Starting dose (first 4 weeks)	Typical maintenance dose
Semaglutide (Wegovy)	0.25 mg weekly	2.4 mg weekly
Tirzepatide (Zepbound)	2.5 mg weekly	5–15 mg weekly

Per the FDA labels, the opening dose exists for one reason: to let your gut adapt. Semaglutide’s 0.25 mg is roughly a tenth of the target dose; tirzepatide’s 2.5 mg is not even an approved maintenance dose. Neither is chosen to drive appetite suppression on its own — they are a ramp. So a small or slow first month isn’t a defect; it’s the design. The bigger effects arrive as you titrate up over the following weeks. We walk through those step-ups in detail in our guide to semaglutide and tirzepatide titration schedules.

Appetite changes usually come before the scale moves

Many people notice the drug before the scale does. The common early experience is a drop in appetite and in “food noise” — the background hum of thinking about food — often within the first week or two of starting or stepping up. Meals feel smaller, cravings ease, and you get full faster.

That matters because it’s the mechanism doing its job. Weight loss is the downstream result of eating less over time; the appetite change is the upstream cause you feel first. If the scale is flat in week two but your portions are visibly smaller, that is the drug working, not failing.

What “normal” looks like in month one

Early loss varies enormously between people, and the first month is the noisiest stretch of the whole journey. A few honest framings:

• A slow first month is common. You are on the lowest dose for those weeks. Expect the pace to pick up as you titrate.
• Water weight and daily fluctuation swamp the signal early. A 2–3 lb swing day to day is normal noise; judge the trend over weeks, not mornings.
• Some people barely move in month one and respond strongly later — and vice versa. Early loss is a weak predictor of where you’ll end up.

The one thing month one does reliably bring for many people is side effects, which is a separate issue from whether the drug is working. Nausea, constipation, and fatigue tend to peak right after starting and after each dose increase. What the trials report about these — how common, how severe, how long — is covered in our summary of GLP-1 side effects from the trials. It’s worth reading, because the first month is also when most people are tempted to quit: the reasons behind that early drop-off are the subject of our piece on the side-effect curve and why most quit in month one.

When to check in with your prescriber

Onset questions occasionally point to something worth flagging. Reach out to your clinician if:

• Side effects are severe or aren’t easing after the first weeks.
• You’ve reached a maintenance dose and held it for a few months with essentially no change (a possible sign of limited response).
• Anything feels beyond ordinary GI upset — persistent vomiting, severe abdominal pain, or dehydration.

None of these are about the drug “starting” — they’re about tolerability and fit, which are decisions to make with a prescriber, not alone.

The takeaway

GLP-1 weight loss starts earlier than most people expect — measurable by week 4 in the STEP-1 trial — but month one is a ramp, not the main event. The starting dose is a tolerability step, appetite changes usually precede visible loss, and a slow or noisy first month is normal rather than a red flag. The real story of these drugs plays out over roughly a year.

To see a realistic month-by-month arc instead of fixating on week one, run your numbers through our GLP-1 weight loss projector, and for the full arc of starting and staying on treatment, see our complete GLP-1 guide.

This article is educational and not medical advice. Individual onset and response vary; questions about your own treatment belong with a qualified clinician.

Sources

• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021 (PubMed)
• Wegovy (semaglutide) prescribing information — DailyMed (FDA label)
• Zepbound (tirzepatide) prescribing information — DailyMed (FDA label)